Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Research & Development (2022 - 2025)

Historic Research & Development for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $25.7 million.

  • Taysha Gene Therapies' Research & Development rose 7225.34% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.8 million, marking a year-over-year increase of 2117.81%. This contributed to the annual value of $66.0 million for FY2024, which is 1624.4% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Research & Development stood at $25.7 million for Q3 2025, which was up 7225.34% from $20.1 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Research & Development high stood at $38.2 million for Q1 2022, and its period low was $11.8 million during Q3 2023.
  • Its 4-year average for Research & Development is $18.4 million, with a median of $15.6 million in 2025.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 6722.54% in 2023, then surged by 7225.34% in 2025.
  • Taysha Gene Therapies' Research & Development (Quarter) stood at $12.7 million in 2022, then dropped by 0.2% to $12.7 million in 2023, then grew by 20.84% to $15.3 million in 2024, then soared by 67.99% to $25.7 million in 2025.
  • Its Research & Development was $25.7 million in Q3 2025, compared to $20.1 million in Q2 2025 and $15.6 million in Q1 2025.